Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Feb 23;11(2):e0005375.
doi: 10.1371/journal.pntd.0005375. eCollection 2017 Feb.

Unexpectedly high leprosy seroprevalence detected using a random surveillance strategy in midwestern Brazil: A comparison of ELISA and a rapid diagnostic test

Affiliations
Comparative Study

Unexpectedly high leprosy seroprevalence detected using a random surveillance strategy in midwestern Brazil: A comparison of ELISA and a rapid diagnostic test

Marco Andrey C Frade et al. PLoS Negl Trop Dis. .

Abstract

Background: Leprosy diagnosis is mainly based on clinical evaluation, although this approach is difficult, especially for untrained physicians. We conducted a temporary campaign to detect previously unknown leprosy cases in midwestern Brazil and to compare the performance of different serological tests.

Methods: A mobile clinic was stationed at the main bus terminal in Brasília, Brazil. Volunteers were quizzed and given a clinical exam to allow categorization as either patients, known contacts of patients or non-contacts, and blood was collected to determine anti-PGL-I and anti-LID-1 antibody titers by ELISA and by the NDO-LID rapid test. New cases of leprosy and the impact of performing this broad random surveillance strategy were evaluated. Accuracy values and concordance between the test results were evaluated among all groups.

Results: Four hundred thirty-four individuals were evaluated, and 44 (10.1%) were diagnosed with leprosy. Borderline forms were the most frequent presentation. Both tests presented higher positivity in those individuals with multibacillary disease. Serological tests demonstrated specificities arround 70% for anti-PGL-1 and anti-LID ELISA; and arround 40% for NDO-LID. Sensitivities ranged from 48 to 62%. A substantial agreement between NDO-LID and ELISA with concomitant positive results was found within leprosy patients (Kappa index = 0.79 CI95% 0.36-1.22).

Conclusions: The unexpectedly high leprosy prevalence in this population indicates ongoing community-based exposure to Mycobacterium leprae antigens and high rates of subclinical infection. All tests showed low specificity and sensitivity values and therefore cannot be considered for use as stand-alone diagnostics. Rather, considering their positivity among MB patients and non-patients, these tests can be considered effective tools for screening and identifying individuals at high risk who might benefit from regular monitoring.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Residency history of leprosy cases identified in the temporary clinic.
The 44 leprosy cases identified during the surveillance period, reported their residency based on state. Red arrow: Federal district. (A)—At the time of survey, 34 were resident in the Federal District, 9 in neighboring Goiás and 1 was living in Mato Grosso. (B)—For patients residing in the Federal District, further delineation was made to their current administrative region. (C and D)—Each case identified their state of origin.

References

    1. World Health Organization. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities 2006–2010. Operational guidelines. Lepr Rev. 2006;77(3):IX, X, 1–50. - PubMed
    1. Cardona-Castro N, Beltrán-Alzate JC, Romero-Montoya M. Clinical, bacteriological and immunological follow-up of household contacts of leprosy patients from a post-elimination area—Antioquia, Colombia. Mem Inst Oswaldo Cruz. 2009;104(6):935–6. - PubMed
    1. World Health Organization. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser. 2012(968):1–61, 1 p following - PubMed
    1. Meima A, Smith WC, van Oortmarssen GJ, Richardus JH, Habbema JD. The future incidence of leprosy: a scenario analysis. Bull World Health Organ. 2004;82(5):373–80. - PMC - PubMed
    1. Alencar CH, Ramos AN, Sena Neto SA, Murto C, Alencar MeJ, Barbosa JC, et al. (Leprosy diagnosis in municipalities other than the patients' place of residence: spatial analysis, 2001–2009). Cad Saude Publica. 2012;28(9):1685–98. - PubMed

Publication types

MeSH terms

Substances